Inhibition of Ferroptosis in Prostatitis Model by Low Intensity Extracorporeal Shock Wave Therapy through the Integrin-β1/NRF2 Axis.

PURPOSE: Although low-intensity extracorporeal shock wave therapy (Li-ESWT) is used clinically for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), its mechanisms remain inadequately understood. This study aimed to explore Li-ESWT-mediated mechanotransduction signaling and its association with ferroptosis in CP/CPPS models. MATERIALS AND METHODS: Experimental autoimmune prostatitis (EAP) was induced by intradermal prostate antigen immunization. Rats received Li-ESWT, with additional groups treated with the ferroptosis inducer RAS-selective lethal 3 (RSL3) or iron chelator deferoxamine (DFO). The rats were analyzed histologically and biochemically to assess immune responses, fibrosis, oxidative stress, ferroptosis markers, and related signaling. RESULTS: EAP rats recapitulated key pathological features of CP/CPPS, which were alleviated by Li-ESWT. Specifically, Li-ESWT reduced the inflammatory response by inhibiting CD3⁺ T cells and CD68⁺ macrophages infiltration, suppressed fibrosis by preventing epithelial-mesenchymal transition and smooth muscle hyperplasia, and attenuated hyperalgesia by inhibiting mast cell degranulation. RSL3 exacerbated these pathological changes, whereas DFO attenuated them. Li-ESWT also suppressed oxidative stress and ferroptosis, as indicated by reduced reactive oxygen species and ferrous iron accumulation, lipid peroxidation, and ferroptosis-driving factors (ACSL4, LPCAT3, ALOX15, COX-2) levels. Li-ESWT also upregulated the Integrin-β1 and NRF2-xCT/GPX4 expression. CONCLUSIONS: Li-ESWT ameliorates inflammation, fibrosis, hyperalgesia in the CP/CPPS model, likely through ferroptosis mitigation